Skip to main content
Scholars@Duke
Menu
About
Schools / Institutes
Browse
construction
release_alert
Profile editing is temporarily unavailable from
June 11-24, 2026
while manual profile data entry transitions to Elements.
Learn More
.
cancel
Nicole Gong Jawitz
Assistant Professor of Medicine
Medicine, Gastroenterology
nicole.jawitz@duke.edu
Research
More About This Person
glance {hide_children: true, active: false, enabled: true}
At a Glance
credentials {hide_children: true, active: false, enabled: true}
Credentials
Education
academic-experience {hide_children: true, active: false, enabled: true}
Academic Experience
Current Appointments & Affiliations
Professional Training and Employment
expertise {hide_children: true, active: false, enabled: false}
Expertise
research {hide_children: false, active: true, enabled: true}
Research
Selected Grants
publications {hide_children: true, active: false, enabled: true}
Publications
Selected Publications
artistic-works {hide_children: true, active: false, enabled: false}
Artistic Works / Events
teaching {hide_children: true, active: false, enabled: false}
Teaching
advising-mentoring {hide_children: true, active: false, enabled: false}
Advising & Mentoring
recognition {hide_children: true, active: false, enabled: false}
Recognition
professional-activities {hide_children: true, active: false, enabled: false}
Professional Activities
Manage Profile
Embed Profile Data
Manage Profile
Embed Profile Data
Selected Grants
A Multicenter, Multinational, Randomized, Double-blind, Placebo-Controlled, Phase 3 Maintenance Study to Evaluate the Efficacy and Safety of Duvakitug in Participants with Moderately to Severely Active Ulcerative Colitis
Clinical Trial
Principal Investigator ·
Awarded by Sanofi US Services, Inc. ·
2026 - 2030
A multicenter, multinational, randomized, double-blind, placebo-controlled Phase 3, maintenance study to evaluate the efficacy and safety of duvakitug in participants with moderately to severely active Crohn's disease
Clinical Trial
Principal Investigator ·
Awarded by Sanofi US Services, Inc. ·
2026 - 2030
Sanofi_EFC18325_Phase 3 Anti-TL1A IBD Program - Ulcerative Colitis Pro00119361
Clinical Trial
Principal Investigator ·
Awarded by Sanofi US ·
2026 - 2030
Sanofi_EFC18326_Phase 3 Anti-TL1A IBD Program - Crohn's Dx Pro00119061
Clinical Trial
Principal Investigator ·
Awarded by Sanofi US ·
2026 - 2030
SPY123-201 Phase 2 Platform Trial to Assess the Efficacy and Safety of Long-acting Antibodies as Single Agents and in Combinations for Moderately to Severely Active Ulcerative Colitis
Clinical Trial
Principal Investigator ·
Awarded by Spyre Therapeutics, Inc. ·
2025 - 2030
